NCI-BL1607 [BL1607, BL9, NCI-BL9]
NCI-BL1607 [BL1607, BL9, NCI-BL9]
规格:
货期:
编号:TS211385
品牌:Testobio
| 产品名称： | NCI-BL1607 BL1607, BL9, NCI-BL9 |
|---|---|
| 商品货号： | TS211385 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Cancer |
| Age： | 54 years |
| Gender： | male |
| Ethnicity： | White |
| Derivation： | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. |
| Clinical Data： | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. The patient was a smoker. male White 54 years |
| Comments： | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. The patient was a smoker. 20 pack years. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(6) viable cells/ml. Maintain cell density between 1 X 10(6) and 3 X 10(6) viable cells/ml. |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 10 D13S317: 9,12 D16S539: 11,13 D5S818: 11,12 D7S820: 8,12 THO1: 9.3 TPOX: 8,11 vWA: 17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| References： | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
NCI-BL1607 [BL1607, BL9, NCI-BL9]
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | NCI-BL1607 BL1607, BL9, NCI-BL9 |
|---|---|
| 商品货号： | TS211385 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Cancer |
| Age： | 54 years |
| Gender： | male |
| Ethnicity： | White |
| Derivation： | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. |
| Clinical Data： | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. The patient was a smoker. male White 54 years |
| Comments： | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. The patient was a smoker. 20 pack years. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(6) viable cells/ml. Maintain cell density between 1 X 10(6) and 3 X 10(6) viable cells/ml. |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 10 D13S317: 9,12 D16S539: 11,13 D5S818: 11,12 D7S820: 8,12 THO1: 9.3 TPOX: 8,11 vWA: 17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| References： | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. |
